首页> 外文OA文献 >FRI0251 SIRUKUMAB, an ANTI-IL-6 cytokine monoclonal antibody, leads to improvements in work productivity and general health status in patients with active rheumatoid arthritis refractory to ANTI-TNF therapy: results from the phase 3 SIRROUND-T study

【2h】

FRI0251 SIRUKUMAB, an ANTI-IL-6 cytokine monoclonal antibody, leads to improvements in work productivity and general health status in patients with active rheumatoid arthritis refractory to ANTI-TNF therapy: results from the phase 3 SIRROUND-T study

机译：Fri0251 Sirukumab，一种抗IL-6细胞因子单克隆抗体，导致有效的类风湿性关节炎患者的工作生产率和一般健康状况，对抗TNF治疗的难治性：结果3 Sirround-T研究结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Y Tanaka; D Aletaha; S Peterson; R Ganguly; R Kurrasch; S Popik; P Agarwal; N Li;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. WORK PRODUCTIVITY AND GENERAL HEALTH STATUS IMPROVEMENTS WITH SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TNF THERAPY: RESULTS FROM THE PHASE 3 SIRROUND-T STUDY [J] . Tanaka Y., Aletaha D., Peterson S., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：在活性类风湿性关节炎患者中，使用抗IL-6细胞因子单克隆抗体的抗IL-6细胞因子单克隆抗体的工作生产力和一般健康状况改善，尽管抗TNF治疗，所以第3期Sirrow-T研究结果
2. WORK PRODUCTIVITY/INTERFERENCE AND GENERAL HEALTH STATUS IMPROVEMENTS WITH SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE TREATMENT WITH DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: RESULTS FROM THE PHASE 3 SIRROUND-D STUDY [J] . Takeuchi T., Karpouzas G., Thorne C., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：西鲁单抗，一种抗IL-6细胞因子单克隆抗体，在患有活动性类风湿关节炎的患者中尽管通过疾病治疗改善了抗风湿性疾病的治疗，但其工作生产率/干扰和总体健康状况得到改善：3
3. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study [J] . Aletaha Daniel, Bingham Clifton O. III, Tanaka Yoshiya, The Lancet . 2017,第10075期

机译：Sirukumab对抗TNF治疗难治性的患者Sirukumab的疗效和安全性（SiRROUD-T）：随机，双盲，安慰剂控制，并行组，跨国，第3期研究
4. A prevalence-based case-control study of the association between mental health and exposure to anti-TNFα biologic therapy: Evidence of a role for macrophage cross-linking by monoclonal antibodies in mental illness [D] . Burns, Craig Francis 2015

机译：基于流行的病例对照研究，研究心理健康与抗TNFα生物治疗的暴露之间的关联：单克隆抗体在精神疾病中巨噬细胞交联作用的证据
5. Extended report: Sirukumab a human anti-interleukin-6 monoclonal antibody: a randomised 2-part (proof-of-concept and dose-finding) phase II study in patients with active rheumatoid arthritis despite methotrexate therapy [O] . Josef S Smolen, Michael E Weinblatt, Shihong Sheng, -1

机译：扩展报告：Sirukumab人类抗白细胞介素6单克隆抗体：一项针对氨甲蝶呤治疗的活动性类风湿关节炎患者的随机2部分（概念验证和剂量确定）II期研究
6. Results of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Sirukumab, An Anti-IL-6 Cytokine Monoclonal Antibody, In Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment (Sirround-D) [O] . T Takeuchi, C Thorne, G Karpouzas, 2016

机译：结果3阶段，随机，双盲，安慰剂对照研究Sirukumab的疗效和安全性，抗IL-6细胞因子单克隆抗体，尽管疾病改性抗风湿药物治疗患者，但是Sirround-D）

FRI0251 SIRUKUMAB, an ANTI-IL-6 cytokine monoclonal antibody, leads to improvements in work productivity and general health status in patients with active rheumatoid arthritis refractory to ANTI-TNF therapy: results from the phase 3 SIRROUND-T study

著录项

相似文献

相关主题

期刊订阅